Lesion Analysis of <sup>18</sup>F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma.
Where this comes from
- Record sourced from PubMed, PMID 40908121.
- Also identified by DOI 10.2967/jnumed.125.269833 and PMC identifier 12487752.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A PET analog of metaiodobenzylguanidine (MIBG)-<sup>18</sup>F-metafluorobenzylguanidine (<sup>18</sup>F-MFBG)-allows for rapid same-day imaging. We previously reported on the safety and feasibility of <sup>18</sup>F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with <sup>18</sup>F-MFBG imaging in patients with neuroblastoma compared with <sup>123</sup>I-MIBG imaging. <b>Methods:</b> We analyzed concurrent <sup>18</sup>F-MFBG and <sup>123</sup>I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11-465.83 MBq (2.0-12.6 mCi) of <sup>18</sup>F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an <sup>123</sup>I-MIBG scan within 4 wk of <sup>18</sup>F-MFBG imaging without any intervening therapy. <sup>123</sup>I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both <sup>123</sup>I-MIBG scans, equivalent scores were ascertained for <sup>18</sup>F-MFBG imaging, and scores were then compared. <b>Results:</b> All patients with a positive <sup>123</sup>I-MIBG scan had positive <sup>18</sup>F-MFBG imaging. In 2 patients, both <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG scans were negative. In 1 patient, the <sup>18</sup>F-MFBG scan was positive, whereas the <sup>123</sup>I-MIBG scan was negative. In 30 of 40 scans, <sup>18</sup>F-MFBG showed more sites than did <sup>123</sup>I-MIBG. Overall, more lesions were noted on the <sup>18</sup>F-MFBG scans (mean, 18; range 0-61) compared with the <sup>123</sup>I-MIBG scans (mean, 12; range, 0-44), and 455 lesions were concordant. The Curie score for <sup>18</sup>F-MFBG was higher, with an average of 11 (range, 0-25) compared with 8 for <sup>123</sup>I-MIBG (range, 0-22). Of the 273 <sup>18</sup>F-MFBG-positive/<sup>123</sup>I-MIBG-negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. <b>Conclusion:</b> <sup>18</sup>F-MFBG PET offers faster imaging and superior detection compared with <sup>123</sup>I-MIBG imaging. <sup>18</sup>F-MFBG had high concordance with <sup>123</sup>I-MIBG at the patient level and showed more lesions in most patients. <sup>18</sup>F-MFBG is an attractive alternative to <sup>123</sup>I-MIBG.
Medical subject headings
- Neuroblastoma
- Positron-Emission Tomography
- Fluorine Radioisotopes
- Guanidines